Quarterly ResultMay 14, 2026, 05:02 PM
Pomdoctor FY25 Revenue +16.7% to RMB399.9M; Net Loss RMB130.9M
AI Summary
Pomdoctor Limited announced its fiscal year 2025 financial results, reporting solid revenue expansion with net revenues increasing 16.7% to RMB399.9 million and gross profit rising 9.6% to RMB52.3 million. The growth was primarily driven by its Internet hospital business, particularly online pharmacy sales. Despite a net loss of RMB130.9 million, largely attributed to significant non-recurring expenses related to its initial public offering and increased R&D investments, the company views these as strategic investments for future growth and market positioning.
Key Highlights
- Net revenues increased 16.7% to RMB399.9 million (US$57.2 million) in fiscal year 2025.
- Gross profit rose 9.6% to RMB52.3 million (US$7.5 million) in fiscal year 2025.
- Net loss was RMB130.9 million (US$18.7 million) in fiscal year 2025, up from RMB37.4 million in 2024.
- Internet hospital net revenues surged 69.3% to RMB150.7 million (US$21.6 million), driven by online pharmacy sales.
- Pharmaceutical supply chain net revenues decreased 1.7% to RMB249.2 million (US$35.6 million).
- Research and development expenses increased 328.5% to RMB12.9 million (US$1.8 million).
- Sales and marketing expenses increased 70.7% to RMB96.2 million (US$13.8 million).
- Company completed its IPO on October 9, 2025, raising US$23.0 million gross proceeds.